Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06122870 · ClinicalTrials.gov registry record · Phase 1
CampETEC Hyperimmune Bovine Colostrum (HBC)
A Phase 1 study, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT06122870 is a Phase 1 study that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 27 participants.
The verdict
NCT06122870, a Phase 1 study, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
Gastrointestinal infections cause significant morbidity in the form of acute diarrheal illness in the United States (US) and among travelers to low- and middle-income countries (LMICs). One approach is to use passive protection (antibodies) to prevent infection. The purpose of this study are to assess the safety and tolerability of serum-derived bovine immunoglobulins in healthy adult subjects when orally administered and to estimate protective efficacy of those preparations against moderate-severe diarrhea upon challenge with Campylobacter C. jejuni strain CG8421.
Interventions
- BIOLOGICAL CampETEC HBC product
- BIOLOGICAL ProMilk 85
- BIOLOGICAL C. jejuni CG8421 Challenge strain
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2025-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06122870
The ClinicalTrials.gov registry entry for NCT06122870 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins Bloomberg School of Public Health, which has 187 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CampETEC HBC product is the first listed.
NCT06122870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06122870 about?
NCT06122870 is a clinical study titled "CampETEC Hyperimmune Bovine Colostrum (HBC)". Gastrointestinal infections cause significant morbidity in the form of acute diarrheal illness in the United States (US) and among travelers to low- and middle-income countries (LMICs). One approach is to use passive protection (antibodies) to prevent infection. The purpose of this study are to asse...
What is the current status of trial NCT06122870?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2023-12-04. Estimated completion is 2025-06-04.
What interventions are being tested in trial NCT06122870?
The interventions under investigation include: CampETEC HBC product (BIOLOGICAL), ProMilk 85 (BIOLOGICAL), C. jejuni CG8421 Challenge strain (BIOLOGICAL).
Who is sponsoring clinical trial NCT06122870?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.